Impact of a Nutritional Supplement on Metabolic Health

Cardiovascular Disease Prevention Clinical Trial

— CHORIBar  

Official title:

Attenuating the Micronutrient Malnutrition of Overnutrition (AMMO)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02239198
• Other study ID #: Nutrition Bar Trials
• Secondary ID: CHORIbar
• Status: Completed
• Phase: N/A
• First received: September 10, 2014
• Last updated: April 17, 2017
• Start date: April 5, 2016
• Est. completion date: April 13, 2017

Study information

• Verified date: February 2017
• Source: Children's Hospital & Research Center Oakland
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There are prevalent micronutrient and fiber deficiencies in a significant proportion of US population, particularly among the overweight or obese. Intensive lifestyle counseling results in modest, measurable dietary improvements and weight stabilization, yet falls short of restoring optimal nutritional status and metabolism. A carefully formulated nutritional supplement bar (referred to as the CHORIBAR) delivered in a whole food matrix may correct micronutrient deficiencies in overweight or obese adults and children. This may have a beneficial impact on traditional indices of insulin dysregulation and the metabolic syndrome, gut inflammation, redox status, immune function and DNA integrity, and may favorably influence weight change and fat distribution.

The investigators believe that the improvements seen with CHORIBAR trials will be mediated at the level of generalized enhancement in cellular metabolism that are not readily achieved with lifestyle counseling alone. The investigators suspect this is due to many nutritional barriers, some of which are disproportionately borne by inner city populations, such as cost and access to healthy food. The investigators hypothesize that a nutritional supplement like the CHORIBAR will facilitate restoration of optimal nutritional status and improve metabolic and weight outcomes.

Description:

With our USDA partners, we have developed a whole-food, multi-component nutrient bars. Previous pilot studies demonstrated that short-term bar consumption results in favorable increases in HDL-cholesterol (HDL-c), particularly large-HDL (HDL-L) in most lean but only in some overweight/obese individuals. Obesity is associated with poor gastrointestinal health and systemic inflammation, which are also associated with low HDL. Our hypothesis is that a carefully formulated nutritional supplement bar delivered in a whole food matrix can correct micronutrient deficiencies in obese adults and have a beneficial impact on indices of insulin dysregulation and the metabolic syndrome. The aims of this project are 1) to characterize the effect size on indices of lipid profile, homocysteine, inflammation, insulin resistance, micronutrient levels, DNA integrity, hunger and satiety, BMI, waist circumference, and blood pressure with different formulations of CHORI bar taken twice daily for periods ranging from 2-8 weeks. We will also evaluate gut inflammation, redox status, tissue metals, and DNA integrity with novel exploratory assays that may serve as markers for micronutrient malnutrition and chronic disease risk. 2) Where significant improvement in the outcome variables is observed, we will attempt to "deconstruct" the bars and attempt to determine the active ingredients responsible for these changes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: April 13, 2017
• Est. primary completion date: April 5, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Either taking no dietary supplements or willing to discontinue any dietary supplements for two weeks preceding the trial.

• Age >18 years

• BMI <40

• Blood pressure <140/90 mmHg, or stable blood pressure on medicines for past 3 months

Exclusion Criteria:

• Known diabetes mellitus according to the 2010 ADA criteria, but pre-diabetic subjects with known impaired glucose tolerance (fasting glucose 101-125, and 2-hour post-prandial glucose level 141-200 mg/dL) can remain eligible.

• Weight loss pharmacotherapy.

• Lipid-lowering medication as this will alter the lipid profile being measured.

• Renal disease as this may affect blood pressure and dietary requirements.

• Smoking

• Pregnancy- a negative urine pregnancy test will be documented for any women participants of childbearing age prior to enrollment.

Related Conditions & MeSH terms

• Cardiovascular Disease Prevention
• Cardiovascular Diseases

Intervention

Other:
• Nutrition bar
The nutrition bar has been formulated to help achieve balanced nutrition with a polyphenolic-rich whole food matrix with vitamins, minerals, omega-3 fatty acids, and fiber at generally physiologic doses intended not to replace but to supplement a typical diet.

Locations

Country	Name	City	State
United States	Children's Hospital & Research Center Oakland	Oakland	California

Sponsors (2)

Lead Sponsor	Collaborator
Children's Hospital & Research Center Oakland	USDA Beltsville Human Nutrition Research Center

Country where clinical trial is conducted

United States, 

References & Publications (1)

Mietus-Snyder ML, Shigenaga MK, Suh JH, Shenvi SV, Lal A, McHugh T, Olson D, Lilienstein J, Krauss RM, Gildengoren G, McCann JC, Ames BN. A nutrient-dense, high-fiber, fruit-based supplement bar increases HDL cholesterol, particularly large HDL, lowers homocysteine, and raises glutathione in a 2-wk trial. FASEB J. 2012 Aug;26(8):3515-27. doi: 10.1096/fj.11-201558. Epub 2012 May 1. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	High density lipoprotein		1 year